|
Apr 29
|
Repligen Reports First Quarter 2025 Financial Results
|
|
Apr 28
|
Repligen (RGEN) Q1 Earnings: What To Expect
|
|
Apr 25
|
3 Healthcare Stocks That Concern Us
|
|
Apr 10
|
Repligen (RGEN): Buy, Sell, or Hold Post Q4 Earnings?
|
|
Apr 8
|
Repligen Appoints Jacob Johnson As Vice President Investor Relations
|
|
Apr 8
|
Repligen (RGEN) Moves 3.7% Higher: Will This Strength Last?
|
|
Mar 12
|
Q4 Earnings Recap: Azenta (NASDAQ:AZTA) Tops Drug Development Inputs & Services Stocks
|
|
Mar 11
|
A Look Back at Drug Development Inputs & Services Stocks’ Q4 Earnings: Repligen (NASDAQ:RGEN) Vs The Rest Of The Pack
|
|
Feb 21
|
Repligen's Q4 Earnings Beat Estimates, Revenues In Line
|
|
Feb 21
|
Repligen Corp (RGEN) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic ...
|
|
Feb 21
|
Q4 2024 Repligen Corp Earnings Call
|
|
Feb 20
|
Repligen Q4 Earnings Momentum Highlights Market Growth, Issues Strong 2025 Outlook
|
|
Feb 20
|
February 2025's US Stocks That May Be Trading Below Fair Value
|
|
Feb 20
|
Repligen (RGEN) Beats Q4 Earnings Estimates
|
|
Feb 20
|
Repligen (NASDAQ:RGEN) Posts Q4 Sales In Line With Estimates
|
|
Feb 20
|
Repligen: Q4 Earnings Snapshot
|
|
Feb 20
|
Repligen Reports Fourth Quarter and Full Year 2024 Financial Results
|
|
Feb 19
|
Earnings To Watch: Repligen (RGEN) Reports Q4 Results Tomorrow
|
|
Feb 18
|
Repligen Corporation's (NASDAQ:RGEN) Intrinsic Value Is Potentially 80% Above Its Share Price
|
|
Feb 12
|
3 Healthcare Stocks Skating on Thin Ice
|